Search

OBJECTIVE: This retrospective study explored the potential connection between adenomyosis and pregnancy outcomes. PATIENTS AND METHODS: A study included data from a total of 1,208 pregnancies. The adenomyosis group included 334 pregnant women with adenomyosis, and women in the control group (n=874) had uncomplicated pregnancies. Data on pregnancy complications and maternal and neonatal outcomes were compared. RESULTS: The incidence of gestational hypertension, gestational diabetes, and placenta previa was higher in the adenomyosis group compared to the control group (p<0.05). Adenomyosis was linked to a higher risk of postpartum hemorrhage (1,000-1,500 ml) but a lower risk of premature rupture of membranes (PROM) (p<0.05). Diagnosis of adenomyosis correlated with increased incidence of low fetal weight (20.3% vs. 21.3%, p<0.05) and a low APGAR score at 1 min (p<0.05). CONCLUSIONS: Adenomyosis correlated with a higher incidence of gestational hypertension, placenta previa, and gestational diabetes. At the same time, adenomyosis correlated with a significantly lower incidence of PROM compared to uncomplicated pregnancy. There was a significant increase in the incidence of postpartum hemorrhage and a higher risk of low fetal weight and lower APGAR score at 1 min in pregnancies with adenomyosis. [ABSTRACT FROM AUTHOR]

An AgBiS2/BiOI composites with different proportions were prepared by precipitation method, and their catalytic activity was studied by degrading RhB (100 mg/L) under simulated light conditions. The results showed that the photocatalytic activity of AgBiS2/BiOI composite was the best when the doping amount of AgBiS2 was 4 wt. % (the degradation rate was about 94%). Compared with pure BiOI, the degradation rate of RhB increased by 24%. After 5 cycles of experiments, the degradation rate of the material can still reach 94%, indicating that the AgBiS2/BiOI composite has good stability. [ABSTRACT FROM AUTHOR]

A CQDs/CoO/g-C3N4 nanocomposite used for photocatalytic degradation was designed and fabricated in this paper. The effects of carbon quantum dots (CQDs) content and synthesis temperature on photocatalytic properties of nanocomposites were studied. The results show that the solar energy utilization efficiency of CQDs/CoO/g-C3N4 nanocomposite is twice that of pure g-C3N4 when the content of CQDs is 4.5 wt%. The improvement of photocatalytic performance of nanocomposite is mainly attributed to the synergistic effect of the junction/interface between g-C3N4, CoO and CQDs. [ABSTRACT FROM AUTHOR]

Perinatal transmission of hepatitis B virus (HBV) contributes to the high prevalence of chronic infection in China and many other countries. In a placebo-controlled trial among 166 infants, the 12-month efficacy of active postexposure prophylaxis to prevent chronic perinatal HBV infection varied by vaccine (range, 45%-89%). In a 5-year follow-up study, 2 additional infants became chronically infected with HBV, and the efficacy of active prophylaxis was estimated to be 38% and 72% for the two vaccines at 5 years. In addition, 80% of immunized infants continued to have protective levels of antibody at the end of 5 years. However, among 27 infants who received passive-active immunoprophylaxis with high-dose hepatitis B immune globulin, only 60% (11/19) had protective antibody levels. These data indicate that active postexposure immunization initiated soon after birth continues to provide protection during early childhood when there is a high risk of chronic HBV infection. [ABSTRACT FROM AUTHOR]

A*31:65: one nucleotide change resulting in a new motif CAC at codon 84 in HLA-A. [ABSTRACT FROM AUTHOR]

B*35:189: one nucleotide change resulting in a new motif GGG at codon 35 in HLA-B. [ABSTRACT FROM AUTHOR]

HLA-A*26:74, one nucleotide change resulting in a new motif ACG at codon 138. [ABSTRACT FROM AUTHOR]

The new allele DRB1*03:80 has a single nucleotide change at position 239(C→G) in exon 2 from the closest matching allele DRB1*03:06. [ABSTRACT FROM AUTHOR]

A novel human leukocyte antigen (HLA)-B allele, B*5535, has been identified in a Chinese individual by sequence-based typing, which has seven nucleotide changes from the closest matching allele B*5502 resulting in two amino acids changes: 69 Glu→Met; 70 Glu→Ala. [ABSTRACT FROM AUTHOR]

Efficient UV excitable Ce3+ ion activated SrWO4 phosphors, which were successfully prepared through a hydrothermal method. X-ray diffraction, field-emission scanning electron microscopy, CIE color coordinates and photoluminescence were used to characterize the samples. The effect of adding pH solution on the luminescent properties of SrWO4: Ce3+ was studied, the luminescence material SrWO4:Ce3+ exhibits intense blue photoluminescence (PL) with the maximum peak located at 306 nm, which is ascribed to the 4f→5d transition of Ce3+, All these results indicate that the SrWO4: Ce3+ phosphor holds tremendous potential for practical applications in and display with high performance LEDs. [ABSTRACT FROM AUTHOR]

Amplification of the HER-2/neu oncogene was assessed in 80 cases of epithelial ovarian tumors using differential polymerase chain reaction. HER-2/neu gene was amplified in 22 of 46 invasive cancers (48%) and in 5 of 34 borderline cancers (15%), but none of the 20 specimens of normal ovaries showed amplification. THis difference is statistically significant (p = 0.00004). The incidence of HER-2/neu amplification in late stage (III-IV, 77%) was significantly higher than that in early stage (I-II, 21%) in invasive epithelial carcinoma (p = 0.0004). There was no correlation between HER-2/neu amplification and cell type or grade of tumor. In cases of ovarian tumors of borderline malignant potential, the amplification of HER-2/neu was not correlated with clinicopathologic features. Follow-up with a mean of 22 months (6-50 months) was available for 39 cases of invasive ovarian cancers and all 34 borderline ovarian cancers. The incidence of HER-2/neu amplification in the invasive cancer and borderline cancer patients who were alive with disease was 50 and 50%, and is not statistically different from that in the patients who were alive with no evidence of disease (p = 0.662 and 0.345, respectively). The incidence of amplification in the invasive cancers of patients who died of the disease (86%) was higher than that in the patients who were still alive (44%), but the difference is not statistically significant (p = 0.175). This study supports the association of HER-2/neu amplification with progression of invasive ovarian cancer. It also suggests that HER-2/neu amplification may be an adjunctive prognostic factor of invasive epithelial ovarian cancer, shown to be associated with an unfavorable clinical course. In addition, HER-2/neu amplification occurs relatively infrequently in early invasive and borderline ovarian cancers, making it unlikely that such amplification is a general early event in ovarian carcinogenesis.